Julie A. Johnson

26.2k total citations · 3 hit papers
346 papers, 14.1k citations indexed

About

Julie A. Johnson is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, Julie A. Johnson has authored 346 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Molecular Biology, 95 papers in Cardiology and Cardiovascular Medicine and 94 papers in Pharmacology. Recurrent topics in Julie A. Johnson's work include Pharmacogenetics and Drug Metabolism (94 papers), Hormonal Regulation and Hypertension (64 papers) and Receptor Mechanisms and Signaling (38 papers). Julie A. Johnson is often cited by papers focused on Pharmacogenetics and Drug Metabolism (94 papers), Hormonal Regulation and Hypertension (64 papers) and Receptor Mechanisms and Signaling (38 papers). Julie A. Johnson collaborates with scholars based in United States, United Kingdom and China. Julie A. Johnson's co-authors include Taimour Langaee, Larisa H. Cavallari, Rhonda M. Cooper‐DeHoff, Yan Gong, Lorraine F. Meisner, William E. Evans, Rajiv Kumar, Teri E. Klein, A.J. Cross and Joseph P. Grande and has published in prestigious journals such as Nature, The Lancet and Circulation.

In The Last Decade

Julie A. Johnson

337 papers receiving 13.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells

2003 759 citations Julie A. Johnson et al. profile →
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

2013 680 citations Teri E. Klein, Julie A. Johnson et al. profile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

2020 194 citations Cameron D. Thomas, Nihal El Rouby et al. profile →

Peers

Countries citing papers authored by Julie A. Johnson

Since Specialization

Citations

This map shows the geographic impact of Julie A. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie A. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie A. Johnson more than expected).

Fields of papers citing papers by Julie A. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie A. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie A. Johnson. The network helps show where Julie A. Johnson may publish in the future.

Co-authorship network of co-authors of Julie A. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Julie A. Johnson. A scholar is included among the top collaborators of Julie A. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie A. Johnson. Julie A. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers 2024 ·Clinical and Translational Science ·(unknown), Caitrin W. McDonough, Steven M. Smith, Yan Gong, John G. Gums, Arlene B. Chapman, Julie A. Johnson, Rhonda M. Cooper‐DeHoff	1
2	Circulating microRNA Biomarkers of Thiazide Response in Hypertension 2024 ·Journal of the American Heart Association ·(unknown), (unknown), Taimour Langaee, Daqing Wang, Rolf Renne, Arlene B. Chapman, John G. Gums, Eric Boerwinkle, Rhonda M. Cooper‐DeHoff, Julie A. Johnson	4
3	A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps 2023 ·Pharmacogenomics and Personalized Medicine ·(unknown), David Estores, Emily J. Cicali, Kristin Wiisanen, Julie A. Johnson	7
4	Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study 2022 ·Genes ·Nicole D. Armstrong, Vinodh Srinivasasainagendra, (unknown), (unknown), (unknown), Alana Jones, Rikki M. Tanner, Bertha Hidalgo, Nita A. Limdi, Steven A. Claas, Yan Gong, Caitrin W. McDonough, Rhonda M. Cooper‐DeHoff, Julie A. Johnson, Hemant K. Tiwari, Donna K. Arnett, Marguerite R. Irvin	5
5	Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma 2022 ·Cancers ·Bei Wang, Benjamin A. Derman, (unknown), Julie A. Johnson, Wei Zhang, Andrzej Jakubowiak, Brian C.‐H. Chiu	6
6	Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients 2022 ·Metabolites ·(unknown), Caitrin W. McDonough, Steven M. Smith, Yan Gong, John G. Gums, Arlene B. Chapman, Julie A. Johnson, Rhonda M. Cooper‐DeHoff	6
7	Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients 2021 ·Metabolites ·(unknown), Caitrin W. McDonough, Steven M. Smith, Yan Gong, John G. Gums, Arlene B. Chapman, Julie A. Johnson, Lauren M. McIntyre, Rhonda M. Cooper‐DeHoff	8
8	A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management 2021 ·Genetics in Medicine ·Cameron D. Thomas, Hari K. Parvataneni, Chancellor F. Gray, Justin T. Deen, Hernan A. Prieto, Luis Pulido, Amanda R. Elsey, (unknown), Petr Starostik, Yan Gong, Roger B. Fillingim, Julie A. Johnson, Larisa H. Cavallari	25
9	CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial 2019 ·Genetics in Medicine ·D. Max Smith, Kristin Weitzel, Amanda R. Elsey, Taimour Langaee, Yan Gong, Dyson T. Wake, Benjamin Q. Duong, (unknown), Christopher A. Harle, (unknown), (unknown), Kimberly J. Newsom, Ashleigh Wright, Eric I. Rosenberg, Petr Starostik, Michael Clare‐Salzler, Siegfried Schmidt, Roger B. Fillingim, Julie A. Johnson, Larisa H. Cavallari	105
10	Genome-wide association analysis of common genetic variants of resistant hypertension 2018 ·The Pharmacogenomics Journal ·(unknown), Nihal El Rouby, Caitrin W. McDonough, Yan Gong, Leslie A. McClure, Braxton D. Mitchell, Richard B. Horenstein, Robert L. Talbert, Dana C. Crawford, Matthew A. Gitzendanner, Atsushi Takahashi, Toshihiro Tanaka, Michiaki Kubo, Carl J. Pepine, Rhonda M. Cooper‐DeHoff, Oscar Benavente, Alan R. Shuldiner, Julie A. Johnson	16
11	Baseline predictors of central aortic blood pressure: A PEAR substudy 2014 ·Journal of the American Society of Hypertension ·(unknown), (unknown), Steven M. Smith, Xuerong Wen, Yan Gong, John G. Gums, Wilmer W. Nichols, Arlene B. Chapman, Eric Boerwinkle, Julie A. Johnson, Benjamin J Epstein	9
12	Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12 , A1BG , and the Selectin Region and Cardiovascular Outcomes 2013 ·Hypertension ·Caitrin W. McDonough, Yan Gong, Sandosh Padmanabhan, Ben Burkley, Taimour Langaee, Olle Melander, Carl J. Pepine, Anna F. Dominiczak, Rhonda M. Cooper‐DeHoff, Julie A. Johnson	27
13	Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study 2013 ·PLoS ONE ·Caitrin W. McDonough, Nancy Gillis, Abdullah Alsultan, (unknown), Marina Kawaguchi‐Suzuki, Jason E. Lang, Mohamed H. Shahin, Thomas W. Buford, (unknown), (unknown), Taimour Langaee, John G. Gums, Arlene B. Chapman, Rhonda M. Cooper‐DeHoff, Stephen T. Turner, Yan Gong, Julie A. Johnson	11
14	Cholesteryl Ester Transfer Protein (CETP) Polymorphisms Affect mRNA Splicing, HDL Levels, and Sex-Dependent Cardiovascular Risk 2012 ·PLoS ONE ·Audrey C. Papp, Julia K. Pinsonneault, Daqing Wang, Leslie C. Newman, Yan Gong, Julie A. Johnson, Carl J. Pepine, Meena Kumari, Aroon D. Hingorani, Philippa J. Talmud, Sonia Shah, Steve E. Humphries, Wolfgang Sadée	45
15	Very important pharmacogene summary ADRB2 2009 ·Pharmacogenetics and Genomics ·Augusto A. Litonjua, Li Gong, Qing Duan, Jaekyu Shin, (unknown), Scott T. Weiss, Julie A. Johnson, Teri E. Klein, Russ B. Altman	70
16	Studies of the Southern Izu-Bonin-Mariana (IBM) Forearc using Shinkai 6500: Watery Glimpses of an In Situ Forearc Ophiolite 2008 ·AGUFM ·Yasuhiko Ohara, Mark K. Reagan, Sherman H. Bloomer, P. Fryer, (unknown), Rosemary L. Hickey-Vargas, (unknown), T. Ishii, Osamu Ishizuka, Julie A. Johnson, Katsuyoshi Michibayashi, (unknown), R. J. Stern, (unknown)	4
17	Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation 2008 ·Journal of Translational Medicine ·Michael Pacanowski, Issam Zineh, Haihong Li, B. Delia Johnson, Rhonda M. Cooper‐DeHoff, Vera Bittner, Dennis M. McNamara, Barry L. Sharaf, C. Noel Bairey Merz, Carl J. Pepine, Julie A. Johnson	24
18	New tools for the manipulation of microspore gene expression 2005 ·Acta Biologica Cracoviensia. Series Zoologia ·David Honys, (unknown), (unknown), Julie A. Johnson, (unknown), Jan Douda, David Twell	1
19	Immunohistochemical detection and distribution of the 1,25-dihydroxyvitamin D3 receptor in rat reproductive tissues 1996 ·Histochemistry and Cell Biology ·Julie A. Johnson, Joseph P. Grande, Patrick C. Roche, Rajiv Kumar	97
20	Adverse effects of flurazepam in a hemodialysis patient. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Julie A. Johnson, (unknown), (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact